|本期目录/Table of Contents|

[1]曲昌华,于凤霞,杨海燕,等.阿托伐他汀对低氧性肺动脉压的影响[J].医学研究与战创伤救治(原医学研究生学报),2012,14(02):120-122.
　QU Chang-hua,YU Feng-xia,YANG Hai-yan,et al.Effects of atorvastatin on pulmonary hypertension in chronic obstructive pulmonary disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(02):120-122.
点击复制

阿托伐他汀对低氧性肺动脉压的影响()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第14卷
期数:
2012年02期
页码:
120-122
栏目:
出版日期:
2012-03-20

文章信息/Info

Title:
Effects of atorvastatin on pulmonary hypertension in chronic obstructive pulmonary disease
文章编号:
1672-271X(2012)02-0120-03
作者:
曲昌华; 于凤霞; 杨海燕; 范民忠; 康丽君
264001 山东烟台，烟台市烟台山医院
Author(s):
QU Chang-hua; YU Feng-xia; YANG Hai-yan; FAN Min-zhong; KANG Li-jun.
Yantaishan Hospital,Yantai,Shandong 264001,China
关键词:
阿托伐他汀;  肺动脉高压;  内皮素;  一氧化氮
Keywords:
atorvastatin;  pulmonary artery pressure;  endothelin;  nitric oxide
分类号:
R563.9
DOI:
-
文献标志码:
A
摘要:
目的 研究他汀类药物治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)合并肺动脉高压(pulmonary hypertension，PH)的疗效和机制。方法 选择2007年1月至2010年5月在我院诊治的COPD合并PH 100例，随机分为治疗组和对照组各50例。对照组给予常规治疗；治疗组在常规治疗基础上加用阿托伐他汀,首剂10~20 mg/d，若无不良反应，则维持剂量10 mg/d，疗程6个月，观察一氧化氮(nitric oxide,NO)、内皮素(endotheli,ET)、肺动脉收缩压(pulmonary artery systolic pressure，PAP)、6分钟步行距离(6-minute walking distance，6MWD)的变化。结果 治疗后，两组6MWD、NO较治疗前升高，PAP、ET降低，差异有统计学意义(P＜0.01)，但治疗组较对照组更明显，差异有统计学意义(P＜0.01)。Spearman相关分析:ET与PAP呈正相关(r=0.452)，NO数值与PAP呈负相关(r=-0.557)。结论 阿托伐他汀能降低COPD合并PH患者肺动脉压，改善患者心肺功能及运动耐量。其机制可能与阿托伐他汀能增加NO含量，降低ET的分泌，改善内皮功能有关。
Abstract:
Objective To observe the effects and mechanism of atorvastatin treatment on patients with chronic obstructive pulmonary disease(COPD) combining with pulmonary hypertension(PH).Methods One hundred patients with COPD combining with PH from January 2007 to May 2010 were assigned randomly to two groups: treatment group(n=50) and control group(n=50).Patients in the control group were given with oxygen therapy,vasodilator,anticoagulant,anti-infection and so on.Patients in the treatment group were given with atorvastatin in addition to the treatment on control group for 6 months.The first dose was 10-20 mg/d and sustained dose was 10 mg/d.The changes of PAP,6MWD,NO,and ET were measured.Results After 6 month treatment,ET,PAP in the two groups decreased significantly(all P<0.01) while NO,6MWD increased significantly(all P<0.01).However,the change of the indexes in treatment group was more obvious than that in control group.Conclusion Atorvastatin can reduce PAP and improve exercise tolerance of COPD patients combining with PH.The mechanism may be that atorvastatin can reduce ET,improve NO and the function of vascular endothelial.

参考文献/References:

[1]张珍祥.肺动脉高压诊断和治疗进展[J].实用医院临床杂志,2007，4(1):5-8.
[2]荆志成,胡大一.肺动脉高压康复指南[M].3版.北京:人民军医出版社,2006:69-70.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17.
[4]ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories．ATS statement: guidelines for the six-minute walk test[J].Am J Respir Crit Care Med，2002，166(1):111-117．
[5]李 琦，余志龙，郑大东.他汀类药物在心血管疾病中的临床应用进展[J].东南国防医药，2011,14(5):438-439,474.
[6]Reed RM,Iacono A,DeFilippis A,et,al.Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD[J].COPD,2011,8(2):96-102.
[7]Zhou Q,Liao JK.Pleiotropic effects of statins.Basic research and clinical perspectives[J].Circ J，2010，74(5):818-826.
[8]Hida W,Tun Y,Kikuchi Y,et al.Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management[J].Respirology,2002,7(1):3-13．
[9]Laufs U，Gertz K，Dirnagl U，et al．Rosuvastatin，a new HM G CoA reductase inhibitor， upregulates endothelial nitricoxide synthase and protects from ischemic stroke in mice[J].Brain Res，2002，942(12):23-30．
[10]Carratu P，Scoditti C,Maniscalco M，et al．Exhaled and arterial level of endothelin-l are increased and correlate with pulmonary systolic pressure in COPD with pulmonary hypertension[J].BMC Pulm Med，2008,8:20.
[11]Lee SD,Lee JH,Kim EK,et al.Effects of simvastatin on cigarette smoking-induced structural and functional changes in rat lungs[J].Chest,2005,128(6 Suppl):574S.
[12]Miyamoto S,Nagaya N,Satoh T,et al.Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension．Comparison with cardiopulmonary exercise testing[J].Am J Respir Crit Care Med,2000,161(2 Pt 1):487-492.

相似文献/References:

[1]丁雪燕,罗助荣.急性冠脉综合征血清脑钠肽水平及 阿托伐他汀对其影响[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):37.
　DING Xue-yan,LUO Zhu-rong.Levels of pro-B-type natriuretic peptide in patients with acute coronary syndrome and the effect of atorvastatin on them[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(02):37.
[2]任绍学,陈亨芸,罗助荣.阿托伐他汀治疗老年冠心病合并血脂异常48例[J].医学研究与战创伤救治(原医学研究生学报),2008,10(04):293.

备注/Memo

备注/Memo:
烟台市科技发展计划项目(2010314)
更新日期/Last Update: 2012-03-20